Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  European journal of medicinal chemistry

• Publication date

  2016-11-29

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejmech.2016.08.034PMID 27569197
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New agents for the treatment of drug-resistant Mycobacterium tuberculosis.

  2016cited by this paper
• 4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.

  2015cited by this paper
• Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.

  2015cited by this paper
• Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors.

  2015cited by this paper
• Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.

  2015cited by this paper
• Lead selection and characterization of antitubercular compounds using the Nested Chemical Library.

  2015cited by this paper
• An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition.

  2014cited by this paper
• Development of novel N-linked aminopiperidine-based mycobacterial DNA gyrase B inhibitors: scaffold hopping from known antibacterial leads.

  2014cited by this paper
• ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use

  2014cited by this paper
• Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.

  2014cited by this paper
• Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B.

  2013cited by this paper
• Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosis.

  2013cited by this paper
• Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.

  2013cited by this paper
• Emergence and Spread of Extensively and Totally Drug-Resistant Tuberculosis, South Africa

  2013cited by this paper
• Advances in the development of new tuberculosis drugs and treatment regimens

  2013cited by this paper
• Nonfluoroquinolone-Based Inhibitors of Mycobacterial Type II Topoisomerase as Potential Therapeutic Agents for TB

  2012cited by this paper
• Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis.

  2012cited by this paper
• Discovery of a novel azaindole class of antibacterial agents targeting the ATPase domains of DNA gyrase and Topoisomerase IV.

  2012cited by this paper
• The Naphthoquinone Diospyrin Is an Inhibitor of DNA Gyrase with a Novel Mechanism of Action

  2012cited by this paper
• Structure-based discovery of substituted 4,5'-bithiazoles as novel DNA gyrase inhibitors.

  2012cited by this paper
• Tuberculosis and HIV Co-Infection

  2012cited by this paper
• Pyrrolamide DNA gyrase inhibitors: optimization of antibacterial activity and efficacy.

  2011cited by this paper
• Novel targets in M. tuberculosis: search for new drugs.

  2011cited by this paper
• Pyrrolamide DNA Gyrase Inhibitors: Fragment-Based Nuclear Magnetic Resonance Screening To Identify Antibacterial Agents

  2011cited by this paper
• The challenge of new drug discovery for tuberculosis

  2011cited by this paper
• Methionine aminopeptidases from Mycobacterium tuberculosis as novel antimycobacterial targets.

  2010cited by this paper
• The Mycobacterium tuberculosis Proteasome Active Site Threonine Is Essential for Persistence Yet Dispensable for Replication and Resistance to Nitric Oxide

  2010cited by this paper
• Self-poisoning of Mycobacterium tuberculosis by targeting GlgE in an alpha-glucan pathway.

  2010cited by this paper
• Discovery of pyrazolthiazoles as novel and potent inhibitors of bacterial gyrase.

  2010cited by this paper
• CarD is an essential regulator of rRNA transcription required for Mycobacterium tuberculosis persistence.

  2009cited by this paper
• Inhibitors Selective for Mycobacterial versus Human Proteasomes

  2009cited by this paper
• Mycolic acid cyclopropanation is essential for viability, drug resistance, and cell wall integrity of Mycobacterium tuberculosis.

  2009cited by this paper
• Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis

  2009cited by this paper
• Dequalinium, a New Inhibitor of Mycobacterium tuberculosis Mycothiol Ligase Identified by High-Throughput Screening

  2009cited by this paper
• High Content Screening Identifies Decaprenyl-Phosphoribose 2′ Epimerase as a Target for Intracellular Antimycobacterial Inhibitors

  2009cited by this paper
• Discovery of novel nitrobenzothiazole inhibitors for Mycobacterium tuberculosis ATP phosphoribosyl transferase (HisG) through virtual screening.

  2008cited by this paper
• Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids.

  2008cited by this paper
• Selectivity of TMC207 towards Mycobacterial ATP Synthase Compared with That towards the Eukaryotic Homologue

  2008cited by this paper
• Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.

  2008cited by this paper
• The Peptidoglycan of Stationary-Phase Mycobacterium tuberculosis Predominantly Contains Cross-Links Generated by l,d-Transpeptidation

  2008cited by this paper
• Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.

  2008cited by this paper
• Mechanism of Action of the Antibiotic NXL101, a Novel Nonfluoroquinolone Inhibitor of Bacterial Type II Topoisomerases

  2008cited by this paper
• Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis*

  2008cited by this paper
• Diarylquinolines target subunit c of mycobacterial ATP synthase.

  2007cited by this paper
• In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice

  2007cited by this paper
• Mycobacterium tuberculosis DNA gyrase as a target for drug discovery.

  2007cited by this paper
• Challenges in tuberculosis drug research and development

  2007cited by this paper
• Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase.

  2006cited by this paper
• Trans-cyclopropanation of mycolic acids on trehalose dimycolate suppresses Mycobacterium tuberculosis -induced inflammation and virulence.

  2006cited by this paper
• Peptide Deformylase Inhibitors as Potent Antimycobacterial Agents

  2006cited by this paper
• Deletion of a Mycobacterium tuberculosis proteasomal ATPase homologue gene produces a slow-growing strain that persists in host tissues.

  2006cited by this paper
• In silico fragment-based discovery of indolin-2-one analogues as potent DNA gyrase inhibitors.

  2005cited by this paper
• Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence

  2005cited by this paper
• A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis

  2005cited by this paper
• Recent advances in understanding structure-function relationships in the type II topoisomerase mechanism.

  2005cited by this paper
• The Proteasome of Mycobacterium tuberculosis Is Required for Resistance to Nitric Oxide

  2003cited by this paper
• Genes required for mycobacterial growth defined by high density mutagenesis

  2003cited by this paper
• Pharmacokinetic Interactions with Rifampicin

  2003cited by this paper
• Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages

  2003cited by this paper
• Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis

  2003cited by this paper
• A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: Application to Mycobacterium tuberculosis

  2003cited by this paper
• Mycothiol Is Essential for Growth of Mycobacterium tuberculosis Erdman

  2003cited by this paper
• Starvation Survival Response of Mycobacterium tuberculosis

  2003cited by this paper
• Inhibition of Respiration by Nitric Oxide Induces a Mycobacterium tuberculosis Dormancy Program

  2003cited by this paper
• N-Alkyl Urea Hydroxamic Acids as a New Class of Peptide Deformylase Inhibitors with Antibacterial Activity

  2002cited by this paper
• Mycothiol-Deficient Mycobacterium smegmatis Mutants Are Hypersensitive to Alkylating Agents, Free Radicals, and Antibiotics

  2002cited by this paper
• An Open Conformation of the Thermus thermophilusGyrase B ATP-binding Domain*

  2002cited by this paper
• Locking the ATP-operated clamp of DNA gyrase: probing the mechanism of strand passage.

  2001cited by this paper
• DNA topoisomerases: structure, function, and mechanism.

  2001cited by this paper
• Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening.

  2000cited by this paper
• A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis.

  2000cited by this paper
• Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase

  2000cited by this paper
• Dimerization of Escherichia coli DNA-gyrase B Provides a Structural Mechanism for Activating the ATPase Catalytic Center*

  2000cited by this paper
• Probing the two-gate mechanism of DNA gyrase using cysteine cross-linking.

  1999cited by this paper
• A model for the mechanism of strand passage by DNA gyrase.

  1999cited by this paper
• Identification of a residue involved in transition-state stabilization in the ATPase reaction of DNA gyrase.

  1998cited by this paper
• Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme.

  1998cited by this paper
• Identifying Lys359 as a Critical Residue for the ATP-dependent Reactions of Drosophila DNA Topoisomerase II*

  1998cited by this paper
• DNA gyrase, topoisomerase IV, and the 4-quinolones

  1997cited by this paper
• The high‐resolution crystal structure of a 24‐kDa gyrase B fragment from E. coli complexed with one of the most potent coumarin inhibitors, clorobiocin

  1997cited by this paper
• Is death inevitable with multiresistant TB plus HIV infection?

  1997cited by this paper
• Design, synthesis and evaluation of a novel series of spiroketals basedon the structure of the antibacterial gyrase inhibitor novobiocin

  1997cited by this paper
• Footprinting of Yeast DNA Topoisomerase II Lysyl Side Chains Involved in Substrate Binding and Interdomainal Interactions*

  1997cited by this paper
• Probing the role of the ATP-operated clamp in the strand-passage reaction of DNA gyrase.

  1996cited by this paper
• DNA topoisomerases.

  1996cited by this paper
• The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X‐ray crystallography.

  1996cited by this paper
• The mechanisms of DNA topoisomerases.

  1995cited by this paper
• Linker insertion mutagenesis of Drosophila topoisomerase II. Probing the structure of eukaryotic topoisomerase II.

  1994cited by this paper
• Synthesis and in vitro antibacterial activity of new semi-synthetic noviosylcoumarin antibiotics: chemical modification at the C-3′ ester

  1994cited by this paper
• Cyclothialidine, a novel DNA gyrase inhibitor. I. Screening, taxonomy, fermentation and biological activity.

  1994cited by this paper
• Pharmacokinetic interaction between rifampin and zidovudine

  1993cited by this paper
• The interaction between coumarin drugs and DNA gyrase

  1993cited by this paper
• The 43-kilodalton N-terminal fragment of the DNA gyrase B protein hydrolyzes ATP and binds coumarin drugs.

  1993cited by this paper
• DNA gyrase: structure and function.

  1991cited by this paper
• Characterization of the ATP binding site on Escherichia coli DNA gyrase. Affinity labeling of Lys-103 and Lys-110 of the B subunit by pyridoxal 5'-diphospho-5'-adenosine.

  1990cited by this paper
• Synthesis and in vitro activity of new semi-synthetic coumermycin analogs: chemical modification at the C-3 amide.

  1989cited by this paper
• The DNA dependence of the ATPase activity of DNA gyrase.

  1984cited by this paper
• DNA gyrase: affinity chromatography on novobiocin-Sepharose and catalytic properties.

  1981cited by this paper
• The intrinsic ATPase of DNA gyrase.

  1980cited by this paper
• Energy coupling in DNA gyrase and the mechanism of action of novobiocin.

  1978cited by this paper

• Analytical and clinical validation of a novel MeltPlus TB-NTM/RIF platform for simultaneous detection of Mycobacterium tuberculosis complex, Non-Tuberculous Mycobacteria and rifampicin resistance

  2025cites this paper
• The Emerging Landscape of Tubercular Targets: A Medicinal Chemistry Approach

  2025cites this paper
• Investigation of the anticancer activity of modified 4-hydroxyquinolone analogues: in vitro and in silico studies

  2025cites this paper
• Design, synthesis, in silico studies, molecular docking, ADMET and anticancer activity of novel N-substituted-4-pyrazole derivatives.

  2025cites this paper
• Chemical Space Exploration and Reinforcement Learning for Discovery of Novel Benzimidazole Hybrid Antibiotics

  2025cites this paper
• Elucidating the Substrate Specificity of Cytochrome P450 Enzymes: Insights into N- and S-Containing Small-Molecule Metabolism

  2025cites this paper
• Recent Developments in Structurally Diverse Anti-Tubercular Drug Molecules and Their Molecular Targets Against Mycobacterium tuberculosis

  2025cites this paper
• Synthesis and Multifaceted Exploration of 4-Phenylpiperidin-4-ol Substituted Pyrazole: Photophysical Insights with Biological Activity

  2024cites this paper
• Fungal phthalimidines-chemodiversity, bioactivity and biosynthesis of a unique class of natural products

  2024cites this paper
• Synthesis and Anti-Mycobacterium Activity of Some New N-Rich Heterocyclic Derivatives and Their Molecular Docking, and DFT Studies

  2024cites this paper
• Efficient construction of functionalized pyrroloindolines through cascade radical cyclization/intermolecular coupling

  2024cites this paper
• Photophysical and In Vitro-In Silico Studies on Newly Synthesized Ethyl 3-((3-Methyl-1-phenyl-1H-pyrazol-5-yl)oxy)-2-methyleneheptanoate

  2024cites this paper
• A Review of Approaches to the Metallic and Non-Metallic Synthesis of Benzimidazole (BnZ) and Their Derivatives for Biological Efficacy

  2023cites this paper
• Synthesis, modeling, and biological studies of new thiazole-pyrazole analogues as anticancer agents

  2023cites this paper
• Protein targets in Mycobacterium tuberculosis and their inhibitors for therapeutic implications: A narrative review.

  2023cites this paper
• Isoflavonoid and Furanochromone Natural Products as Potential DNA Gyrase Inhibitors: Computational, Spectral, and Antimycobacterial Studies

  2023cites this paper
• Computational Approaches for the Structure-Based Identification of Novel Inhibitors Targeting Nucleoid-Associated Proteins in Mycobacterium Tuberculosis

  2023cites this paper
• Synthesis, X-Ray Structure Analysis, Computational Investigations, and In Vitro Biological Evaluation of New Thiazole-Based Heterocycles as Possible Antimicrobial Agents

  2023cites this paper
• Synthesis and Biological Screening of New 2-(5-Aryl-1-phenyl-1H-pyrazol-3-yl)-4-aryl Thiazole Derivatives as Potential Antimicrobial Agents

  2023cites this paper
• Nontuberculous mycobacterial pulmonary disease and the potential role of SPR720

  2023cites this paper
• A Fluorescence-Based, T5 Exonuclease-Amplified DNA Cleavage Assay for Discovering Bacterial DNA Gyrase Poisons

  2023cites this paper
• Identification of potential Escherichia coli DNA gyrase B inhibitors targeting antibacterial therapy: an integrated docking and molecular dynamics simulation study

  2023cites this paper
• An overview of antibiotic and antibiotic resistance

  2022cites this paper
• Development of a Predictive Model for Inhibitory Activity of Thiazolopiridinyl-ureas on Mycobacterial DNA Gyrase Subunit B using Molecular Descriptors

  2022cites this paper
• Three Component Cascade Reaction of Cyclohexanones, Aryl Amines, and Benzoylmethylene Malonates: Cooperative Enamine-Brønsted Acid Approach to Tetrahydroindoles

  2022cites this paper
• Formation of nitrogen-containing six-membered heterocycles on steroidal ring system: A review.

  2022cites this paper
• Synthesis of Novel Thiazole Derivatives Bearing β-Amino Acid and Aromatic Moieties as Promising Scaffolds for the Development of New Antibacterial and Antifungal Candidates Targeting Multidrug-Resistant Pathogens

  2021cites this paper
• Design and synthesis of new 3-((7-chloroquinolin-4-yl)amino)thiazolidin-4-one analogs as Mycobacterium tuberculosis DNA gyrase inhibitors

  2021cites this paper
• Facile One-Pot Multicomponent Synthesis of Pyrazolo-Thiazole Substituted Pyridines with Potential Anti-Proliferative Activity: Synthesis, In Vitro and In Silico Studies

  2021cites this paper
• GyrB inhibitors as potential antibacterial agents: a review

  2021cites this paper
• Novel thiomorpholine tethered isatin hydrazones as potential inhibitors of resistant Mycobacterium tuberculosis.

  2021cites this paper
• Novel N-bridged pyrazole-1-carbothioamides with potential antiproliferative activity: design, synthesis, in vitro and in silico studies.

  2021cites this paper
• Recent updates in natural terpenoids as potential anti-mycobacterial agents.

  2021cites this paper
• Synthesis and Antimicrobial Evaluation of Some New Pyrazole Derivatives Containing Thiazole Scaffolds

  2021cites this paper
• Extensively Drug-resistant Tuberculosis (XDR-TB)-inhibitors to Overcome the Scourge of Drug-resistant Tuberculosis: a Perspective

  2020cites this paper
• An overview of new antitubercular drugs, drug candidates, and their targets

  2020cites this paper
• Structure-based drug repurposing to inhibit the DNA gyrase of Mycobacterium tuberculosis.

  2020cites this paper
• Novel anti-tubercular and antibacterial based benzosuberone-thiazole moieties: Synthesis, molecular docking analysis, DNA gyrase supercoiling and ATPase activity.

  2020cites this paper
• Synthesis and in vitro antitubercular activity of pyridine analouges against the resistant Mycobacterium tuberculosis.

  2020cites this paper
• Pyridine and quinoline molecules as crucial protagonists in the never-stopping discovery of new agents against tuberculosis.

  2020cites this paper
• Highlights Regarding The Use Of Metallic Nanoparticles Against Pathogens Considered A Priority By The World Health Organization.

  2020cites this paper
• A Review on Recent Advances in Nitrogen-Containing Molecules and Their Biological Applications

  2020cites this paper
• Advancement of GyrB inhibitors for treatment of infections caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.

  2020cites this paper
• Thiazolyl-pyrazole derivatives as potential antimycobacterial agents.

  2019cites this paper
• In silico study directed towards identification of the key structural features of GyrB inhibitors targeting MTB DNA gyrase: HQSAR, CoMSIA and molecular dynamics simulations

  2019cites this paper
• Design, efficient synthesis and molecular docking of some novel thiazolyl-pyrazole derivatives as anticancer agents

  2019cites this paper
• A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity.

  2019cites this paper
• Synthesis of new thiazolyl-pyrazolyl-1,2,3-triazole derivatives as potential antimicrobial agents.

  2019cites this paper
• 3D QSAR-based design and liquid phase combinatorial synthesis of 1,2-disubstituted benzimidazole-5-carboxylic acid and 3-substituted-5H-benzimidazo[1,2-d][1,4]benzodiazepin-6(7H)-one derivatives as anti-mycobacterial agents.

  2019cites this paper
• Chemical classes targeting energy supplying GyrB domain of Mycobacterium tuberculosis.

  2018cites this paper
• Characterization of new, efficient Mycobacterium tuberculosis topoisomerase-I inhibitors and their interaction with human ABC multidrug transporters

  2018cites this paper
• Antibacterial small molecules targeting the conserved TOPRIM domain of DNA gyrase

  2017cites this paper
• Therapeutic evolution of benzimidazole derivatives in the last quinquennial period.

  2017cites this paper
• Hybrids of thienopyrimidinones and thiouracils as anti-tubercular agents: SAR and docking studies.

  2017cites this paper
• Design, synthesis and 2D QSAR study of novel pyridine and quinolone hydrazone derivatives as potential antimicrobial and antitubercular agents.

  2017cites this paper
• Liquid phase combinatorial synthesis of 1,2,5-trisubstituted benzimidazole derivatives as human DHODH inhibitors.

  2017cites this paper